Icure Pharmaceutical (XKRX:175250) ROCE % : -20.20% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Icure Pharmaceutical's annualized ROCE % for the quarter that ended in Mar. 2024 was -20.20%.

Icure Pharmaceutical ROCE % Historical Data

The historical data trend for Icure Pharmaceutical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical ROCE % Chart

Icure Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-4.09

-5.02

-20.78

-26.07

-29.04

Icure Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-21.17	-17.46	-5.44	-70.26	-20.20

Icure Pharmaceutical ROCE % Calculation

Icure Pharmaceutical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-26835.921	/	( ( (224120.549 - 109980.866)	+	(166137.497 - 95438.915) )	/ 2 )
	=	-26835.921	/	( (114139.683	+	70698.582)	/ 2 )
	=	-26835.921	/	92419.1325
	=	-29.04 %

Icure Pharmaceutical's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-13814.104	/	( ( (166137.497 - 95438.915)	+	(162618.092 - 96516.947) )	/ 2 )
	=	-13814.104	/	( ( 70698.582	+	66101.145 )	/ 2 )
	=	-13814.104	/	68399.8635
	=	-20.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Icure Pharmaceutical (XKRX:175250) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Icure Pharmaceutical ROCE % Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Icure Pharmaceutical (XKRX:175250) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR

Website

https://www.icure.co.kr

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical (XKRX:175250) Headlines

No Headlines